66 related articles for article (PubMed ID: 18425964)
1. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.
Khouri C; Lepelley M; Bailly S; Blaise S; Herrick AL; Matucci-Cerinic M; Allanore Y; Trinquart L; Cracowski JL; Roustit M
Lancet Rheumatol; 2019 Dec; 1(4):e237-e246. PubMed ID: 38229380
[TBL] [Abstract][Full Text] [Related]
3. The use of acupuncture in patients with Raynaud's syndrome: a systematic review and meta-analysis of randomized controlled trials.
Zhou F; Huang E; Zheng E; Deng J
Acupunct Med; 2023 Apr; 41(2):63-72. PubMed ID: 35608095
[TBL] [Abstract][Full Text] [Related]
4. What are the effects of vasodilators in patients with primary Raynaud's phenomenon? A Cochrane review summary with commentary.
Coskun Benlidayi I
Int J Rheum Dis; 2022 Feb; 25(2):232-235. PubMed ID: 34845840
[No Abstract] [Full Text] [Related]
5. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.
Khouri C; Blaise S; Carpentier P; Villier C; Cracowski JL; Roustit M
Br J Clin Pharmacol; 2016 Jul; 82(1):6-16. PubMed ID: 26949933
[TBL] [Abstract][Full Text] [Related]
6. Raynaud's phenomenon: no net effects of vasodilators in a network analysis.
Jaeger VK; Walker UA
Lancet Rheumatol; 2019 Dec; 1(4):e200-e202. PubMed ID: 38229370
[No Abstract] [Full Text] [Related]
7. Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.
Nawaz I; Nawaz Y; Nawaz E; Manan MR; Mahmood A
Cureus; 2022 Jan; 14(1):e21681. PubMed ID: 35242466
[TBL] [Abstract][Full Text] [Related]
8. A serious case of primary Raynaud's phenomenon in an infant.
Kobayashi M; Takano KI; Kamizono J; Ichikawa K
Clin Case Rep; 2018 Nov; 6(11):2089-2091. PubMed ID: 30455897
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial of Acupressure for the Treatment of Raynaud's Phenomenon: The difficulty of conducting a trial in Raynaud's phenomenon.
Gladue H; Berrocal V; Harris R; Tsou PS; Edhayan G; Ohara R; Khanna D
J Scleroderma Relat Disord; 2016; 1(2):226-233. PubMed ID: 27840853
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.
Gladue H; Maranian P; Paulus HE; Khanna D
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):630-6. PubMed ID: 22972592
[TBL] [Abstract][Full Text] [Related]
11. Primary Raynaud's phenomenon in an infant: a case report and review of literature.
Sharathkumar AA; Castillo-Caro P
Pediatr Rheumatol Online J; 2011 Jul; 9():16. PubMed ID: 21767369
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of Raynaud's phenomenon.
Levien TL
Vasc Health Risk Manag; 2010 Mar; 6():167-77. PubMed ID: 20448801
[TBL] [Abstract][Full Text] [Related]
13. Oral vasodilators for primary Raynaud's phenomenon.
Vinjar B; Stewart M
Cochrane Database Syst Rev; 2008 Apr; (2):CD006687. PubMed ID: 18425964
[TBL] [Abstract][Full Text] [Related]
14. Oral vasodilators for primary Raynaud's phenomenon.
Stewart M; Morling JR
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD006687. PubMed ID: 22786498
[TBL] [Abstract][Full Text] [Related]
15. Vasodilators for primary Raynaud's phenomenon.
Su KY; Sharma M; Kim HJ; Kaganov E; Hughes I; Abdeen MH; Ng JHK
Cochrane Database Syst Rev; 2021 May; 5(5):CD006687. PubMed ID: 33998674
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
